Tularemia vaccine development: paralysis or progress?

Vaccine (Auckl). 2016:6:9-23. doi: 10.2147/VDT.S85545. Epub 2016 May 4.

Abstract

Francisella tularensis (Ft) is a gram-negative intercellular pathogen and category A biothreat agent. However, despite 15 years of strong government investment and intense research focused on the development of a US Food and Drug Administration-approved vaccine against Ft, the primary goal remains elusive. This article reviews research efforts focused on developing an Ft vaccine, as well as a number of important factors, some only recently recognized as such, which can significantly impact the development and evaluation of Ft vaccine efficacy. Finally, an assessment is provided as to whether a US Food and Drug Administration-approved Ft vaccine is likely to be forthcoming and the potential means by which this might be achieved.

Keywords: Sex bias; cellular immunity; differential protection; humoral immunity; media impact.